NCT05416359

Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

TQB3915 is a selective estrogen receptor covalent antagonist, by covalently binding to estrogen receptor, by changing the conformation of ERα, blocking intracellular signal transmission, thereby inhibiting the growth of tumor cells.

Conditions

• Advanced Malignant Tumor

Interventions

Type	Name	Description
DRUG	TQB3915 tablets	TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.

Timeline

• Start date: 2022-06-01
• Primary completion: 2023-06-01
• Completion: 2024-06-01
• First posted: 2022-06-13
• Last updated: 2022-06-13

Locations

3 sites across 1 country: China